Algiax Pharmaceuticals is a clinical-stage biotechnology company established in 2011.
It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need.
Algiax’ lead candidate AP-325 is a small-molecule GABAA receptor modulator in clinical development as a therapy for neuropathic pain.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.